SIP
MACK

Stoneridge Investment Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Stoneridge Investment Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,103
Closed -$99K – 315
2017
Q2 		$99K Sell
10,103
-15,219
-60% -$311K 0.01% 237
2017
Q1 		$614K Sell
25,322
-2,874
-10% -$71.9K 0.08% 208
2016
Q4 		$905K Hold
28,196
– – 0.12% 186
2016
Q3 		$1.41M Buy
28,196
+5,250
+23% +$218K 0.2% 150
2016
Q2 		$973K Hold
22,946
– – 0.15% 175
2016
Q1 		$1.51M Sell
22,946
-3,527
-13% -$184K 0.22% 127
2015
Q4 		$1.65M Buy
26,473
+11,073
+72% +$779K 0.22% 125
2015
Q3 		$1.03M Buy
15,400
+6,374
+71% +$520K 0.14% 156
2015
Q2 		$878K Sell
9,026
-697
-7% -$66.3K 0.11% 175
2015
Q1 		$909K Sell
9,723
-8,896
-48% -$757K 0.11% 181
2014
Q4 		$1.66M Sell
18,619
-35,522
-66% -$2.59M 0.22% 133
2014
Q3 		$3.74M Buy
54,141
+4,441
+9% +$237K 0.55% 61
2014
Q2 		$2.85M Buy
49,700
+38,477
+343% +$1.95M 0.43% 77
2014
Q1 		$445K Buy
11,223
+607
+6% +$26K 0.09% 131
2013
Q4 		$445K Hold
10,616
– – 0.09% 129
2013
Q3 		$317K Buy
+10,616
New +$371K 0.07% 150

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stoneridge Investment Partners's MACK Position: Q3 2017 in Review

Stoneridge Investment Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 10,103 shares — an estimated $99K sold.

Stoneridge Investment Partners first reported a position in MACK in Q3 2013 and held it in 16 quarters. The position peaked at $3.74M in Q3 2014. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Stoneridge Investment Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 10,103 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $99K.
  • Stoneridge Investment Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 16 quarters.
  • Stoneridge Investment Partners's Merrimack Pharmaceuticals, Inc. position peaked at $3.74M in Q3 2014.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Stoneridge Investment Partners's 13F filing for Q3 2017, filed 2 Nov 2017.